PHGE insider filings
BiomX Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-03-18. Screen PHGE transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PHGE between 2026-07-26 and 2026-10-24. The table below lists the most recent filings on record.
Recent insider filings — BiomX Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-18 | 4 | Yeganeh Reuven — Director, 10% owner | Conversion (C): 450,000 @ $2 · Sale (S): 450,000 @ $5 · Conversion (C): 530,000 @ $2 · Sale (S): 530,000 @ $5 · Conversion (C): 900 (derivative) @ $0 · Conversion (C): 1,060 (derivative) @ $0 · +3 more | EDGAR |
| 2026-03-13 | 4 | Yeganeh Reuven — Director, 10% owner | Conversion (C): 300,000 @ $2 · Sale (S): 300,000 @ $5 · Conversion (C): 370,000 @ $2 · Sale (S): 370,000 @ $5 · Conversion (C): 600 (derivative) @ $0 · Conversion (C): 740 (derivative) @ $0 | EDGAR |
| 2025-04-23 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director Deerfield Mgmt V, L.P. — Director Deerfield Mgmt HIF, L.P. — Director Deerfield Private Design Fund V, L.P. — Director Deerfield Healthcare Innovations Fund II, L.P. — Director | Grant/award (A): 1,611,864 (derivative) · Grant/award (A): 1,611,864 (derivative) | EDGAR |
| 2025-04-21 | 4/A | Merril Gregory Louis — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Bassan Merav — Chief Development Officer | Grant/award (A): 79,597 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 126,748 @ $0 · Grant/award (A): 380,500 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | GOODMAN JESSE — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Moses Alan Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Blum Susan — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Greig Russell — Director | Grant/award (A): 35,200 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Wolfson Marina — Chief Financial Officer | Grant/award (A): 68,545 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Williams Eddie — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | LEFF JONATHAN S — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Wolfson Marina — Chief Financial Officer | Grant/award (A): 68,545 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Greig Russell — Director | Grant/award (A): 35,200 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | GOODMAN JESSE — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Bassan Merav — Chief Development Officer | Grant/award (A): 79,597 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Moses Alan Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 126,748 @ $0 · Grant/award (A): 380,500 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Blum Susan — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Williams Eddie — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Cystic Fibrosis Foundation — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-03-03 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director Deerfield Mgmt V, L.P. — Director Deerfield Mgmt HIF, L.P. — Director Deerfield Private Design Fund V, L.P. — Director Deerfield Healthcare Innovations Fund II, L.P. — Director | Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 1,611,863 (derivative) · Option exercise (M): 1,611,863 (derivative) · Grant/award (A): 1,258,614 (derivative) · Grant/award (A): 1,258,614 (derivative) | EDGAR |
| 2024-09-18 | 4 | Bassan Merav — Chief Development Officer | Grant/award (A): 31,749 @ $0 | EDGAR |
| 2024-09-18 | 4 | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 50,556 @ $0 | EDGAR |
| 2024-09-18 | 4 | Oron Assaf — Chief Business Officer | Grant/award (A): 25,804 @ $0 | EDGAR |
| 2024-07-17 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director Deerfield Mgmt V, L.P. — Director Deerfield Mgmt HIF, L.P. — Director Deerfield Private Design Fund V, L.P. — Director Deerfield Healthcare Innovations Fund II, L.P. — Director | Option exercise (M): 5,883,000 · Option exercise (M): 5,883,000 · Option exercise (M): 5,883 (derivative) · Option exercise (M): 5,883 (derivative) | EDGAR |
| 2024-07-15 | 4 | Blum Susan — Director | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Greig Russell — Director | Grant/award (A): 352,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Bassan Merav — Chief Development Officer | Grant/award (A): 950,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Wolfson Marina — Chief Financial Officer | Grant/award (A): 950,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 3,805,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | GOODMAN JESSE — Director | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Merril Gregory Louis — Director | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Oron Assaf — Chief Business Officer | Grant/award (A): 237,500 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Moses Alan Charles — Director | Grant/award (A): 176,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Williams Eddie — Director | Grant/award (A): 176,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-11 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director, 10% owner Deerfield Mgmt V, L.P. — Director, 10% owner Deerfield Mgmt HIF, L.P. — Director, 10% owner Deerfield Private Design Fund V, L.P. — 10% owner Deerfield Healthcare Innovations Fund II, L.P. — Director, 10% owner | Grant/award (A): 722,175 (derivative) · Grant/award (A): 722,175 (derivative) · Grant/award (A): 20,175,000 (derivative) · Grant/award (A): 20,175,000 (derivative) | EDGAR |
| 2024-05-20 | 4 | OrbiMed Israel BioFund GP Limited Partnership — 10% owner OrbiMed Israel GP Ltd. — 10% owner GORDON CARL L — 10% owner Chimovits Erez — 10% owner | Option exercise/expiry (X): 9,280,408 @ $0.24 · Sale (S): 24,344 @ $0.38 · Option exercise/expiry (X): 9,280,408 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Cystic Fibrosis Foundation — 10% owner | Option exercise/expiry (X): 4,778,265 @ $0.00 · Option exercise/expiry (X): 4,778,265 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | OrbiMed Israel BioFund GP Limited Partnership — 10% owner OrbiMed Israel GP Ltd. — 10% owner GORDON CARL L — 10% owner Chimovits Erez — 10% owner | Purchase (P): 4,327 (derivative) · Purchase (P): 2,163,500 (derivative) | EDGAR |
| 2024-03-19 | 4 | Flynn James E — Director, 10% owner DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director, 10% owner Deerfield Mgmt V, L.P. — Director, 10% owner Deerfield Mgmt HIF, L.P. — Director, 10% owner Deerfield Private Design Fund V, L.P. — 10% owner Deerfield Healthcare Innovations Fund II, L.P. — Director, 10% owner | Grant/award (A): 3,055,049 · Grant/award (A): 3,055,049 · Grant/award (A): 13,490 (derivative) · Grant/award (A): 13,490 (derivative) · Grant/award (A): 40,350 (derivative) · Grant/award (A): 40,350 (derivative) | EDGAR |
| 2023-12-13 | 4 | Wolfson Marina — Chief Financial Officer | Disposition to issuer (D): 36,000 (derivative) · Grant/award (A): 9,474 (derivative) · Disposition to issuer (D): 33,250 (derivative) · Grant/award (A): 8,750 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Grant/award (A): 35,715 (derivative) | EDGAR |
| 2023-12-13 | 4 | Bassan Merav — Chief Development Officer | Disposition to issuer (D): 47,500 (derivative) · Grant/award (A): 12,500 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Grant/award (A): 71,429 (derivative) | EDGAR |
| 2023-12-13 | 4 | Solomon Jonathan Eitan — Chief Executive Officer, Director | Disposition to issuer (D): 144,000 (derivative) · Grant/award (A): 37,895 (derivative) · Disposition to issuer (D): 152,000 (derivative) · Grant/award (A): 40,000 (derivative) · Disposition to issuer (D): 205,000 (derivative) · Grant/award (A): 146,429 (derivative) | EDGAR |
| 2023-12-13 | 4 | Oron Assaf — Chief Business Officer | Disposition to issuer (D): 31,500 (derivative) · Grant/award (A): 8,290 (derivative) · Disposition to issuer (D): 33,250 (derivative) · Grant/award (A): 8,750 (derivative) | EDGAR |
Recent 8-K events — BiomX Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-23 | 8-K | 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PHGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs